Plain-English translation of ·
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether people with multiple sclerosis can safely switch to receiving ocrelizumab infusions once per year instead of twice per year. After at least 2 years of successful treatment where your disease has been quiet, researchers want to see if spacing out the medication might work just as well while reducing your infection risk and the burden of frequent hospital visits.
Ocrelizumab works very well at controlling multiple sclerosis, but like all immune-suppressing medications, it carries a risk of infection that increases the longer you take it. Early evidence suggests that once your disease is under control, this medication may keep working even with longer breaks between doses — so doctors want to test whether patients can safely receive it less often.
You would be randomly assigned to either keep receiving infusions every 6 months or switch to receiving them once per year. You would visit the hospital for infusions on your assigned schedule and complete regular MRI brain scans to monitor your disease. The study lasts 2 years, during which researchers will track whether your MS stays under control on whichever schedule you receive.
AI-generated summary from trial data · Aug 31, 2026 · Not medical advice
France